You are here

GSK

The big revamp at GlaxoSmithKline R&D includes a new collaboration on AI

The big revamp at GlaxoSmithKline R&D includes a new collaboration on AI

Endpoints

artificial intelligence

Flag link:

GSK Hands Nerve Drug Back to Ionis as RNA Battle Heats Up

GSK Hands Nerve Drug Back to Ionis as RNA Battle Heats Up

Xconomy

familial amyloid polyneuropathy

Flag link:

Pharma's giants, new and old, tell more tales than their numbers show

Pharma's giants, new and old, tell more tales than their numbers show

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Mylan points finger at FDA for failure to win nods on Advair, Copaxone copies

Mylan points finger at FDA for failure to win nods on Advair, Copaxone copies

Fierce Pharma

Teva Pharmaceutical

Flag link:

The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results

The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results

Fierce Pharma

Bristol-Myers Squibb

Flag link:

GSK déjà vu: Time for a top-down switch as new CEO tries to conquer old R&D demons

GSK déjà vu: Time for a top-down switch as new CEO tries to conquer old R&D demons

Endpoints

Flag link:

Gilead Could Be Making An Acquisition — But It's Not What You Think

Gilead Could Be Making An Acquisition — But It's Not What You Think

Investors Business Daily

Gilead Sciences

United Therapeutics

Flag link:

GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn't bode well for Sanofi, AstraZeneca: analyst

GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn't bode well for Sanofi, AstraZeneca: analyst

Fierce Pharma

Flag link:

Vaccines provide a boost for GlaxoSmithKline, Sanofi and Merck in second-quarter financials

Vaccines provide a boost for GlaxoSmithKline, Sanofi and Merck in second-quarter financials

Fierce Pharma

Flag link:

Drugmaker GSK calls for at least two years' Brexit transition

Drugmaker GSK calls for at least two years' Brexit transition

Reuters

Flag link:

GlaxoSmithKline's talk of leaving rare diseases—amid slow Strimvelis sales—highlights challenges in the field

GlaxoSmithKline's talk of leaving rare diseases—amid slow Strimvelis sales—highlights challenges in the field

Fierce Pharma

Flag link:

GSK gets go-ahead for new Benlysta formulation

GSK gets go-ahead for new Benlysta formulation

BioPharma Dive

systemic lupus erythematosus

Flag link:

GSK CEO Walmsley is reorganizing R&D, dropping drugs and adding a new focus on cancer research

GSK CEO Walmsley is reorganizing R&D, dropping drugs and adding a new focus on cancer research

Endpoints

Flag link:

GlaxoSmithKline Names Former Walmart Exec as New CTO

GlaxoSmithKline Names Former Walmart Exec as New CTO

TheStreet.com

Flag link:

Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta

Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta

Endpoints

Samsung Bioepis

Flag link:

GSK to ax hundreds of jobs through manufacturing shuffle

GSK to ax hundreds of jobs through manufacturing shuffle

BioPharma Dive

drug manufacturing

Flag link:

The flu vaccines are coming: GSK, Sanofi ship the first of more than 150M doses headed to U.S.

The flu vaccines are coming: GSK, Sanofi ship the first of more than 150M doses headed to U.S.

Fierce Pharma

Flag link:

GSK puts old antibiotics and UK Horlicks business on the block

GSK puts old antibiotics and UK Horlicks business on the block

Yahoo/Reuters

Flag link:

GlaxoSmithKline woos Pfizer medicinal sciences chief Tony Wood to high-level R&D job

GlaxoSmithKline woos Pfizer medicinal sciences chief Tony Wood to high-level R&D job

Endpoints

Flag link: